Checkpoint Therapeutics Inc (CKPT)
1.63
+0.07
(+4.49%)
USD |
NASDAQ |
May 15, 15:44
Checkpoint Therapeutics Enterprise Value: 46.25M for May 14, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| May 14, 2024 | 46.25M |
| May 13, 2024 | 45.51M |
| May 10, 2024 | 44.03M |
| May 09, 2024 | 46.25M |
| May 08, 2024 | 48.46M |
| May 07, 2024 | 51.04M |
| May 06, 2024 | 46.93M |
| May 03, 2024 | 45.14M |
| May 02, 2024 | 41.57M |
| May 01, 2024 | 38.72M |
| April 30, 2024 | 38.36M |
| April 29, 2024 | 39.97M |
| April 26, 2024 | 39.79M |
| April 25, 2024 | 39.43M |
| April 24, 2024 | 40.15M |
| April 23, 2024 | 39.97M |
| April 22, 2024 | 40.50M |
| April 19, 2024 | 40.86M |
| April 18, 2024 | 45.86M |
| April 17, 2024 | 48.36M |
| April 16, 2024 | 49.07M |
| April 15, 2024 | 50.14M |
| April 12, 2024 | 52.28M |
| April 11, 2024 | 54.06M |
| April 10, 2024 | 52.28M |
| Date | Value |
|---|---|
| April 09, 2024 | 54.06M |
| April 08, 2024 | 53.71M |
| April 05, 2024 | 54.06M |
| April 04, 2024 | 55.49M |
| April 03, 2024 | 57.28M |
| April 02, 2024 | 57.28M |
| April 01, 2024 | 60.85M |
| March 28, 2024 | 68.23M |
| March 27, 2024 | 67.87M |
| March 26, 2024 | 68.94M |
| March 25, 2024 | 66.44M |
| March 22, 2024 | 64.30M |
| March 21, 2024 | 62.88M |
| March 20, 2024 | 62.16M |
| March 19, 2024 | 61.09M |
| March 18, 2024 | 41.95M |
| March 15, 2024 | 42.69M |
| March 14, 2024 | 40.95M |
| March 13, 2024 | 43.43M |
| March 12, 2024 | 44.67M |
| March 11, 2024 | 48.39M |
| March 08, 2024 | 48.02M |
| March 07, 2024 | 48.89M |
| March 06, 2024 | 49.88M |
| March 05, 2024 | 50.38M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
14.03M
Minimum
Dec 08 2022
313.42M
Maximum
Nov 09 2021
97.23M
Average
79.23M
Median
Jan 21 2020
Enterprise Value Benchmarks
| QuidelOrtho Corp | 5.282B |
| Fortress Biotech Inc | -4.172M |
| Anavex Life Sciences Corp | 225.42M |
| Ocugen Inc | 400.80M |
| NovaBay Pharmaceuticals Inc | 3.698M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -10.94M |
| Total Expenses (Quarterly) | 10.95M |
| EPS Diluted (Quarterly) | -0.33 |
| Earnings Yield | -169.9% |
| Normalized Earnings Yield | -228.42 |